Medical Advocates
Atazanavir (Reyataz)
 
Pediatric Data

New and Noteworthy
General Reports
Drug Alerts
 Pharmacokinetics
 Dosing
 Adverse Events
 Efficacy
 Treatment Guidelines
 

  
Atazanavir Main Page New/Newsworthy Home Page      
Last updated:  December 08, 2014
 Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader
New and Noteworthy
     
September 2014
 
General Reports
       

     Journal Abstracts, Papers, and Commentaries

 
A WEEK-IN-REVIEW FEATURED REPORT
 Atazanavir: In Pediatric Patients with HIV-1 infection.
 Deeks ED. 
Paediatr Drugs. 2012 Jan 31.
 Abstract

Atazanavir: In Pediatric Patients with HIV-1 infection.
 Deeks ED.
Paediatr Drugs. 2012 Jan 31.
 Abstract
 

     Conference Reports, Abstracts, and Posters

  Equivalence of boosted atazanavir based regimens and currently effective HAART regimens with other PI’s/NNRTI’s in HIV+ children and adolescents with elevated lipid levels
J. Piatt, J. Foti, K. Bickes, et al
(XX International AIDS Conference)
 Abstract
Drug Alerts
       
 
PACKAGE INSERT PDF UPDATE
 The Reyataz (atazanavir) Capsule label has been updated to include the
dosing recommendations for pediatric patients 6 to 18 years of age.
USFDA
March 26, 2008
 News Release
Pharmacokinetics
 
     Journal Abstracts, Papers, and Commentaries
 
  Pharmacokinetics of Atazanavir/Ritonavir among HIV-Infected Thai Children Concomitantly Taking Tenofovir Disoproxil Fumarate.
Bunupuradah T, Techasaensiri C, Keadpudsa S, et al
Pediatr Infect Dis J. 2014 Jun 30
 Abstract

A WEEK-IN-REVIEW FEATURED REPORT
Population pharmacokinetics of atazanavir/r in HIV-1 infected children and adolescents.
Foissac F, Blanche S, Dollfus C, et al  
Br J Clin Pharmacol. 2011 Jun 8.
Abstract

Atazanavir and Atazanavir/Ritonavir Pharmacokinetics in HIV-Infected Infants, Children,
and Adolescents.
 Kiser JJ, Rutstein RM, Samson P, et al
AIDS. 2011 May 21.
 Abstract

     Conference Reports, Abstracts, and Posters
 
  Population Pharmacokinetics of ATV/r in HIV-1+ Children and Adolescents
 F Foissac S Blanche, C Dollfus, et al
 (12 CROI)
 Abstract

Pharmacokinetics of Atazanavir/Ritonavir in HIV-infected Infants, Children, and
Adolescents: PACTG 1020A
 J Kiser  R Rutstein , G Aldrovandi , et al
(12 CROI)
 Abstract

Dosing
       

     Journal Abstracts, Papers, and Commentaries

 
Model-based Approach for Optimization of Atazanavir Dose Recommendations for HIV-infected Pediatric Patients.
Hong Y, Kowalski KG, Zhang J, et al
Antimicrob Agents Chemother. 2011 Sep 19.
 Abstract
Adverse Events
 
     Conference Reports, Abstracts, and Posters
 
 
POSTER
 Changes in Cholesterol and Triglyceride Levels among Pediatric Patients Treated with
Atazanavir, with or without Ritonavir Boosting: The 1020A NIH PACTG Protocol
 P Samson, R Rutstein, T Fenton,  et al 
(13 CROI)
 PDF Poster     Abstract

Relationship between Low Bone Mass Measurements and Age in HIV-infected Children
and Adolescents on HAART
 S Mora, V Giacomet, L Cafarelli , et al
 (12 CROI)
 Abstract

Effect of Atazanavir on Serum Cholesterol and Triglyceride Levels in HIV-infected Infants,
Children, and Adolescents- PACTG 1020A
 R Rutstein, P Samson, G Aldrovandi, et al
 (12 CROI)
 Abstract
 
Trends in Bacteremia in the Pre- and Post-HAART Eras among HIV-infected Children
in the U.S. Perinatal AIDS Collaborative Transmission Study (1986-2004)
 S Nesheim, M oe, B Kapogiannis, et al
 (12 CROI)
 Abstract
Efficacy
 

     Journal Abstracts, Papers, and Commentaries

  Long-Term Safety and Efficacy of Atazanavir-Based Therapy in HIV-Infected Infants, Children and Adolescents: The Pediatric AIDS Clinical Trials Group Protocol 1020A.
 Rutstein RM, Samson P, Fenton T,  et al 
Pediatr Infect Dis J. 2014 Sep 17.
 Abstract

Change to a Once-Daily Combination Including Boosted Atazanavir in HIV-1-Infected Children.
 Macassa E, Delaugerre C, Teglas JP, et a 
Pediatr Infect Dis J. 2006 Sep;25(9):809-814.
 Abstract
 
     Conference Reports, Abstracts, and Posters
 
  PRINCE 1: 48 week safety and efficacy of atazanavir powder and ritonavir liquid in HIV-1-infected antiretroviral treatment-naïve and -experienced infants and children 3 months to 6 years of age
 R. Strehlau, A. Liberty, A. Pena Donati, et al
 (7TH IAS Conference on HIV Pathogenesis, Treatment and Prevention)
 Abstract

POSTER
Treatment Responses to Atazanavir-containing HAART in a Drug-naïve Pediatric Population
in South Africa
T Meyers R Rutstein, P Samson,
PDF Poster     Abstract
Treatment Guidelines
United States 
 

ARV Drugs Main Page New/Newsworthy Home Page      

Atazanavir Pediatric Data